Operator: Thank you. Our next question is from Stacy Ku with Cowen. Please proceed with your question.
Stacy Ku: Thanks so much for taking our questions. We did have a few. So first, you gave some background about that initial clinician outreach. Can you talk a little bit more about your goals and expectations and the clinician base? I believe you said in the past, it’s around patients for the 40 reps. So any additional details or timing would be appreciated. So that’s the first question. And then the second question is around your ability to, I’m guessing, track the FUROSCIX scripts from your three specialty pharmacies. So — can you just give some really early expectations for how this month is progressing. Are you happy? And I know you’ve talked about the stocking inventory. So how should we just be thinking about the bolus of initial patients especially for those clinicians that might be aware of FUROSCIX.
That’s our second question. And then third, you’ve talked about previously potential targets patients that are being captured before hospitalization as prevention, or post discharge just to see — to make sure they’re completely dry. So is there any, I guess, very, very early initial color on where these patients are coming from. Thank you so much.
John Tucker: Great, Stacy. Thanks, it’s John. So let me just sum up the questions, kind of the number of doctors we’re targeting and kind of initially, what are we hearing out there? And then three, kind of the patient types. So Steve, do you want to tackle those?
Steve Parsons: Yes. I think we shared previously, each territory have about a minimum of 150 targets, up to 200. They can add those as they’re making their way through the territory, learning more about who’s involved in patient care, who’s involved in initiating prescriptions. So anywhere from 6,000 to 8,000 would be our target list that we could see regularly. Of course, there’ll be outliers where we see occasionally. So people — but our commitment would be to see 150 very, very routinely many times a year, covering about 450 hospital communities. So all the doctors that are in and around that hospital on the campus in their medical buildings in their heart failure clinics. So that’s the targeting. We have spot RXs, we get to report every day.
We can see all the prescriptions every single day from our specialty pharmacy and all the different distribution centers. It comes into the central hub. And so far, we’re pleased. I’ve been saying — we’re seeing, as John said, we’re seeing Medicare prescriptions, they’re seeing Medicaid prescriptions, we’re seeing commercial prescriptions. And it’s — that’s what we hope to see.
John Tucker: Yes, it’s funny we’re — some of the things we’re seeing, we saw a prescription for 180 units the other day, which it’s too many really because we don’t want the plans to start looking at that and put in quantity limits on it. So we’ve been pleased by what we’re seeing from a demand standpoint as well. On the patient’s side, it’s interesting. And this is why sometimes it’s a little going to be careful what you see early. We are seeing like this, this group of patients where the doctors that know FUROSCIX is coming have kind of tee them up. And as soon as we detail them and service them. I think it’s important to note, Stacy, that you just can’t order FUROSCIX unless you’ve seen us, unless we’ve done it in service and detailed you on the drug.
